UPCC 06624: A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801 With and Without Pembrolizumab in Patients With Treatment-Refractory, Unresectable Melanoma
Enrolling By Invitation
99 years or below
All
Phase
N/A
1 Location
Brief description of study
The main purpose of this research is to compare progression free survival of subjects with melanoma receiving the experimental drug LNS8801, receiving the study drug and pembrolizumab, and receiving treatment chosen by the study doctor.
We would like to rely on WCG IRB as the IRB of record for this study.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
TBD
Updated on
08 Jan 2025.
Study ID: 857457
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
